Elanco Animal Health (NYSE:ELAN) Research Coverage Started at Barclays

Barclays initiated coverage on shares of Elanco Animal Health (NYSE:ELAN) in a research note released on Tuesday, Marketbeat.com reports. The brokerage issued an overweight rating and a $30.00 price target on the stock.

ELAN has been the topic of several other reports. Zacks Research lowered Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th. Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 15th. KeyCorp started coverage on Elanco Animal Health in a report on Friday, November 21st. They set an “overweight” rating and a $27.00 target price on the stock. JPMorgan Chase & Co. upgraded Elanco Animal Health from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $18.00 to $24.00 in a report on Tuesday, October 7th. Finally, Stifel Nicolaus increased their price objective on shares of Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $22.78.

Elanco Animal Health Trading Down 0.2%

Shares of ELAN opened at $21.26 on Tuesday. Elanco Animal Health has a twelve month low of $8.02 and a twelve month high of $23.70. The firm has a market capitalization of $10.56 billion, a P/E ratio of 354.39, a price-to-earnings-growth ratio of 2.89 and a beta of 1.86. The company has a current ratio of 2.40, a quick ratio of 1.23 and a debt-to-equity ratio of 0.59. The stock’s fifty day simple moving average is $21.72 and its 200 day simple moving average is $17.98.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.06. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same period last year, the business posted $0.13 EPS. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. On average, equities research analysts forecast that Elanco Animal Health will post 0.91 earnings per share for the current year.

Institutional Investors Weigh In On Elanco Animal Health

Several hedge funds and other institutional investors have recently modified their holdings of the stock. SJS Investment Consulting Inc. grew its stake in Elanco Animal Health by 2,563.5% in the third quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock worth $28,000 after purchasing an additional 1,333 shares in the last quarter. Huntington National Bank lifted its holdings in Elanco Animal Health by 136.7% during the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company’s stock worth $38,000 after buying an additional 1,087 shares during the last quarter. Whittier Trust Co. of Nevada Inc. grew its position in shares of Elanco Animal Health by 80.3% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock worth $42,000 after acquiring an additional 900 shares in the last quarter. Farther Finance Advisors LLC grew its position in shares of Elanco Animal Health by 79.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock worth $43,000 after acquiring an additional 951 shares in the last quarter. Finally, First Horizon Advisors Inc. increased its holdings in shares of Elanco Animal Health by 184.3% in the 2nd quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company’s stock valued at $53,000 after acquiring an additional 2,414 shares during the last quarter. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.